TYR Tactical

CRO Pharmaceuticals Announces the Launch of POLYSERP Next Generation Antivenoms

POLYSERP™ offers freeze-dried unrefrigerated snake antivenoms designed specifically for the treatment of envenomation casualties in operational and austere medicine environments. POLYSERP™ antivenoms come in two broad-spectrum, regionally-specific formulations that are indicated for the treatment of neurotoxic, hemotoxic, and cytotoxic snake envenomations by all of the critical threat species in a given area without the need to identify the snake. 

Safe For Field Use

Traditional concerns with antivenoms arose from the high risk of serious reactions such as anaphylaxis, which occurred in as high as 75% of patients treated in some studies on older products. The rate of serious reactions to POLYSERP™ has been reduced to ? 1% thanks to a patented multi-step process of fragmentation, purification, and lyophilization resulting in a product that is free of preservatives and safe enough to administer by direct IV push in a low resource environment.

Unrefrigerated, Freeze-Dried, Field Stable

POLYSERP™ has been designed from the ground up to meet the needs of austere medical providers. Each vial contains a minimum of 500 LD50 neutralization potency against the most dangerous regional snakes. The increased potency allows field providers to treat severe envenomations at the point of injury, reducing the amount of space and weight, while adding an invaluable medical capability.

No Cold-Chain

Snakes are abundant in warm climates due to their cold-blooded physiology, but most antivenoms require constant refrigeration. POLYSERP™ is a next generation product that can be carried in a backpack for 6 months at temperatures exceeding 100º F without any loss of potency, making it the first product that is specifically designed for use in the environments where snakes are most common and disaster is most likely to strike.

US GOVERNMENT SALES

POLYSERP™

228 Park Ave. S. Suite 29413

New York, New York 10003-1502

sales@polyserptherapeutics.com

United States Patent 10,538,577

Learn more at www.polyserptherapeutics.com

Purchase available with physician-sponsor. Please contact sales@polyserptherapeutics.com for ordering information.

2 Responses to “CRO Pharmaceuticals Announces the Launch of POLYSERP Next Generation Antivenoms”

  1. AbnMedOps says:

    Very interesting! Could be a real lifesaver.

  2. Wazza says:

    A interesting development in toxinocolgy and antivenin technology. The problems with snake identification, antivenin administration and cold chain have been identified and addressed .
    I would like to see a similar product here in Australia for our own toxic elapids .